Skip to content
Explore AlphaWorks UK for cutting-edge technology insights,…

Administering Pluripotent Cells During Pregnancy to Babies with Spina Bifida Boosts Life Outcomes, Trial Finds

A pioneering research effort has discovered that providing pluripotent cells to unborn babies diagnosed with spina bifida as part of a surgical repair can be a "significant breakthrough" in addressing congenital conditions.

Trial Details and Safety

The US-based trial focused on six unborn babies with a severe neural tube defect. Doctors administered placenta-derived mesenchymal stem cells to the surface of the baby's spinal cord while the defect was being closed.

Importantly, the cell therapy was found to be safe. The study team reported that the treatment did not lead to cancerous growths, disrupt the healing process, or block the correction of related neurological issues.

Encouraging Results

Imaging conducted after delivery confirmed a successful correction of hindbrain herniation in every participant. This brain structure normalization is closely linked to enhanced physical outcomes.

"Should it enable additional babies to achieve ambulation who wouldn't have, it could establish itself as the new treatment paradigm," noted the study director. "These findings are super exciting and create a pathway toward numerous possible novel therapies."

Future Implications and Hope

Experts not involved in the trial have suggested that subsequent studies of these apparent benefits could signal a "different age" in in-utero treatment. The prospect of enhancing neural deficits occurring during fetal development is regarded as a transformative goal.

Particularly welcome would be better management of bladder and bowel function, which are typical difficulties for those diagnosed with this defect.

Looking Ahead

While this initial trial involved a limited number of patients, its established security and encouraging indicators offer a robust platform for expanded clinical research. The integration of stem cell therapy with proven prenatal surgical methods presents significant potential for changing life trajectories for future generations with myelomeningocele.

AC
Written by

Amy Cole DVM

Tech enthusiast and content strategist with a passion for simplifying complex innovations.

AlphaWorks UK

Type to search articles.